Oxidative and genotoxic damage after radio-iodine therapy of Graves' hyperthyroidism

International Journal of Radiation Biology

Volumn 80, Issue 3, 2004, Pages 209-216

  Ballardin, M ^b   Barsacchi, R ^b   Bodei, L ^e   Caraccio, N ^b   Cristofani, R ^b   Di Martino, F ^c   Ferdeghini, M ^f   Kusmic, C ^d   Madeddu, G ^g   Monzani, F ^b   Rossi, A M ^b   Sbrana, I ^b   Spanu, A ^g   Traino, C ^c   Barale, R ^a,b  

^a Dipto Sci dell'Ambiente Territorio   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CLASTOGEN; IODINE 131; LIPID PEROXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTOXICITY; GRAVES DISEASE; HUMAN; LYMPHOCYTE; MALE; MICRONUCLEUS; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VITAMIN BLOOD LEVEL;

ADULT; AGED; DNA DAMAGE; FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; LIPID PEROXIDES; LYMPHOCYTES; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MIDDLE AGED; OXIDATIVE STRESS; VITAMIN E;

EID: 2342463610     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/0955300042000205555     Document Type: Article

References (32)

1. ANTUNES, L. M. and TAKAHASHI, C. S., 1998, Effects of high doses of Vits C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow cells. Mutation Research, 419, 137-143.
2. BALLARDIN, M., GEMIGNANI, F., BODEI, L., MARIANI, G., FERDEGHINI, M., ROSSI, A. M., MIGLIORE, L. and BARALE, R., 2002, Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutation Research, 514, 77-85.
3. CESARONE, M. R., BELCARO, G., CARRATELLI, M., CORNELLI, U., DE SANCTIS, M. T., INCANDELA, L., BARSOTTI, A., TERRANOVA, R. and NICOLAIDES, A. A., 1999, Simple test to monitor oxidative stress. International Angiology, 18, 127-130.
4. DANINIAK, N. and TANN, B. J., 1995, Utility of biological membranes as indicators for radiation exposure: alterations in membrane structure and function over time. Stem Cells, 13, 142-152.
5. EMERIT, I., 1990, Clastogenic factors: detection and assay. In L. Packer and A. N. Glazer (eds), Methods in Enzymology (New York: Academic Press), pp. 555-564.
6. EMERIT, I., CERNYAVSKI, L., ARUTYUNYAN, R., OGANESYAN, N., POGOSIAN, A., MEJLUMIAN, H., SARKISIAN, T., GULKANDANIAN, M., QUASTEL, M., GOLSMITH, J., RIKILS, E., KORDYSH, R., POLIAK, S. and MERKLIN, L., 1994, Transferable clastogenic activity in plasma from persons exposed as salvage personnel of the Chernobyl reactor. Journal Cancer Research and Clinical Oncology, 120, 558-561.
7. FENECH, M., 1993, The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutation Research, 285, 35-44.
8. FENECH, M. and MORLEY, A. A., 1986, Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low-dose x-irradiation. Mutation Research, 161, 193-198.
9. FERDEGHINI, M., BODEI, L., MONZANI, F., LAZZERI, E., CRISTOFANI, R., CARACCIO, N., BALLARDIN, M., TRAINO, A. C., SPANU, A., DARDANO, A., MADEDDU, G., BARALE, R. and MARIANI, G., 2003, Effect of ginkgo biloba extract in protecting from genotoxic damage during radioiodine therapy: preliminary results. Oral presentation at the Annual Congress of the European Association of Nuclear Medicine - EANM'03, 23-27 August 2003, Amsterdam, the Netherlands. European Journal Nuclear Medicine Molecular Imaging, 2003, 30 (Suppl. 2), S164 (abst).
10. GOLDMAN, M. B., MALOOF, F., MONSON, R. R., ASCHENGRAU, A., COOPER, D. S. and RIDGWAY, E. C., 1988, Radioactive iodine therapy and breast cancer. American Journal of Epidemiology, 127, 969-980.
11. GUTIERREZ, S., CARBONELLI, E., GALOFRE, P., CREUS, A. and MARCOS, R., 1999, Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. European Journal of Nuclear Medicine, 26, 1589-1596.
12. HALL, P., BOICE, J. D., JR, BERG, G., BJELKENGREN, G., ERICSSON, U. B., HALLQUIST, A., LIDBERG, M., LUNDELL, G., MATTSSON, A. and TENNVALL, J., 1992, Leukaemia incidence after iodine-131 exposure. Lancet, 340, 1-4.
13. HALL, P., LUNDELL, G. and HOLM, L. E., 1993, Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinologica, 128, 230-234.
14. HALLIWELL, B. and ARUOMA, O. I., 1991, DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Letters, 281, 9-19.
15. HOFFMAN, D. A., MCCONAHEY, W. M., FRAUMENI, J. F., JR and KURLAND, L. T., 1982, Cancer incidence following treatment of hyperthyroidism. International Journal of Epidemiology, 11, 218-224.
16. KONOPACKA, M. and RZESZOWSKA-WOLNY, J., 2001, Antioxidant Vits C, E and beta-carotene reduce DNA damage before as well as after gamma-ray irradiation of human lymphocytes in vitro. Mutation Research, 491, 1-7.
17. LANG, J. K. and PACKER, L., 1987, Quantitative determination of Vit E and oxidized and reduced coenzyme Q by high-performance liquid chromatography with in-line ultraviolet and electrochemical detection. Journal of Chromatography, 9, 109-117.
18. M'KACHER, R., LEGAL, J. D., SCHLUMBERGER, M., AUBERT, B., BERON-GAILLARD, N., GAUSSEN, A. and PARMENTIER, C., 1997. Sequential biologic dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. Journal of Nuclear Medicine, 38, 377-380.
19. M'KACHER, R., LEGAL, J. D., SCHLUMBERGER, M., VOISIN, P., AUBERT, B., GAILLARD, N. and PARMENTIER, C., 1996, Biologic dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. Journal of Nuclear Medicine, 37, 1860-1864.
20. M'KACHER, R., SCHLUMBERGER, M., LEGAL, J. D., VIOLOT, D., BERON-GAILLARD, N., GAUSSEN, A. and PARMENTIER, C., 1998. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. Journal of Nuclear Medicine, 39, 825-829.
21. PAUWELS, E. K., SMIT, J. W., SLATS, A., BOURGUIGNON, M. and OVERBEEK, F., 2000, Health effects of therapeutic use of 1311 in hyperthyroidism. Quarterly Journal of Nuclear Medicine, 44, 333-339.
22. PINCHEIRA, J., BRAVO, M., SANTOS, M. J., DE LA TORRE, C. and LOPEZ-SAEZ, J. F., 2001, Fanconi anemia lymphocytes: effect of DL-alpha-tocopherol (Vitamin E) on chromatid breaks and on G2 repair efficiency. Mutation Research, 461, 265-271.
23. PINCHEIRA, J., NAVARRETE, M. H., DE LA TORRE, C., TAPIA, G. and SANTOS, M. J., 1999, Effect of vitamin E on chromosomal aberrations in lymphocytes from patients with Down's syndrome. Clinical Genetics, 55, 192-197.
24. 131I) for hyperthyroidism. New England Journal Medicine, 292, 167-171.
25. 131I for thyroid cancer. Journal of Nuclear Medicine, 17, 460-464.
26. SGOUROS, G., 1993, Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. Journal Nuclear Medicine, 34, 689-694.
27. SHACKELFORD, R. E., KAUFMANN, W. K. and PAULES, R. S., 1999, Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environmental Health Perspectives, 107 (Suppl. 1), 5-24.
28. STABIN, M. G., 1996, MIRDOSE the personal computer software for use in internal dose assessment in nuclear medicine. Journal Nuclear Medicine, 37, 538-546.
29. THURNHAM, D. I., DAVIES, J. A., CRUMP, B. J., SITUNAYAKE, R. D. and DAVIS, M., 1986, The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Annals of Clinical Biochemistry, 23, 514-520.
30. 131I therapy of Graves' disease. Radiation Protection Dosimetry, 95, 117-124.
31. WILLEMSEN, U. F., KNESEWITSCH, P., KREISIG, T., PICKARDT, C. R. and KIRSCH, C. M., 1993, Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease. European Journal of Nuclear Medicine, 20, 1051-1055.
32. WOLFRAM, R. M., BUDINSKY, A. C., PALUMBO, B., PALUMBO, R. and SINZINGER, H., 2002, Radioiodine therapy induces dose-dependent in vivo oxidation injury: evidence by increased isoprostane 8-epi-PGF(2 alpha). Journal Nuclear Medicine, 43, 1254-1258.